**PMO-47** CLIPPER (BECLOMETHASONE DIPROPIONATE) AS A TREATMENT FOR CHECKPOINT INHIBITOR INDUCED ENTEROCOLITIS

1James Alexander*, 1Hajir Ibrahim, 1Camilla Richards, 2Ben Shum, 3Polychronis Pavlidis, 3Andrew Furness, 1Julian Teare, 1Ally Speight, 3Sophie Pope, 1Nick Powell. Imperial College, London; 2Royal Marsden Hospital, London; 3King’s College, London; 4Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne

**Introduction** Systemic corticosteroids, the mainstay of treatment for immune checkpoint inhibitor (CPI) induced enterocolitis, are associated with complications including life-threatening infection. The topicically-acting oral corticosteroid Beclomethasone Dipropionate (BD) is an effective treatment for mild to moderate flares of ulcerative colitis, and has fewer side effects than systemic corticosteroids. In this study, we hypothesised that BD is a safe and effective treatment for mild and microscopic CPI enterocolitis.

**Methods** We performed a retrospective analysis of all patients who started BD for CPI enterocolitis at three UK cancer centres between November 2017 & October 2020. All patients underwent endoscopic assessment and biopsy. The initial regimen of BD was 5mg once daily for 28 days. The primary outcome was clinical remission at 28 days, defined as a return to baseline stool frequency. Secondary outcomes included the rates of adverse events and clinical relapse after BD cessation.

**Results** Twenty-two patients (14 male) with a median age of 64 (range 45-84) were treated with BD. At baseline, ten patients (71%) had an increase in stool frequency of greater than 3 per day above baseline (CTCAE grade 2 or more) and the median number of loose stools in a 24-hour period was six. 11 (50%) patients were dependent on systemic corticosteroids prior to starting BD. Baseline sigmoidoscopy showed mild inflammation (loss of vascular pattern, mucosal granularity, small erosions) in eleven patients (50%) and normal findings in eleven patients (50%). Twenty patients (91%) had histopathological features of inflammation. There were no adverse events attributable to BD. All 22 patients (100%) had a clinical response to BD and 21 (95.5%) achieved clinical remission with a return to baseline stool frequency. 10 patients (45.5%) had symptomatic relapse on cessation of BD, five (22.7%) within seven days of stopping. All 10 relapsing patients recaptured response on restarting BD.

**Conclusions** Topical BD is an appealing alternative option to systemic immunosuppressive treatments to treat colonic inflammation. In this study, BD was safe and effective at inducing remission in mild and/or microscopic CPI induced enterocolitis. Further randomised studies are needed to confirm these findings and determine the optimum dosing regimen.

---

**PMO-48** BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD

1Rachael Barrett*, 1Spyros Siakavellas, 1Nickolas Plevris, 1Julia Gauzi, 1Laura Lucaci, 1Ian Amott, 1Lynne Merchant, 1Gareth-Rhys Jones, 1Lauranne Derikx, 1Charles Lees. 1The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; 2Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK

**Introduction** There is extensive data on the safety and effectiveness of switching from originator infliximab to biosimilar infliximab. However, there is relatively little data regarding biosimilar-biosimilar infliximab switch nor on multiple switching. In our tertiary IBD unit, we have now undertaken two managed switch programs for infliximab: 1) Remicade to CT-P13 in 2016 and 2) CT-P13 to Zessly in Q1 2020. We now report the 6 months experience of this second switch.

**Methods** All IBD patients treated with CT-P13 underwent an elective switch to Zessly from March to May 2020. Patients were identified in a prospective biologic prescription database. IBD phenotype, CRP, drug survival, infliximab drug and antibody levels and faecal calprotectin (FCAL) data were collected before and 6 months after switch. Protocol driven treatment adjustments were made in specialized multidisciplinary virtual biologics clinic.

Our main aim was to investigate the outcomes following a switch from an IFX biosimilar CT-P13 (Remsima) to another biosimilar Zessly in IBD, with the primary outcome being drug persistence.

**Results** Overall, 229 IBD patients (CD=165 UC/IBDU=64) were switched from CT-P13 to Zessly. 67/229 (29.2%) patients had been started on Remicade and switched to CT-P13 four years previously, therefore this was their second biosimilar switch (‘double switch’). Drug persistence was excellent at 94.3% for the overall cohort with no significant difference (p=0.26) seen between the CT-P13-Zessly (single switch – 93.2%) or Remicade-CT-P13-Zessly groups (double switch – 97%). Nine patients (3.9%) needed a dose increase. No differences were observed between CRP (±5mg/L), FCAL (±250mcg/g) or clinical (CD: HBI ≤54, UC: pMayo Score ≤1) remission rates comparing before and 6 months post Zessly switch. This was observed for both the total cohort and the single/double switch subgroup. Trough infliximab levels also remained stable pre- and post-switch in both switch subgroups as well as in the total cohort (p = 0.11). Five patients (3.1%) developed new infliximab antibodies after switching from CT-P13 to Zessly, all from the single switch group. 11 patients (4.8%) were switched to another biologic category due to loss of response. Two patients (0.8%) stopped treatment secondary to adverse events (1 due to severe infection and 1 due to exacerbation of arthritis).

**Conclusions** Switching between CT-P13 and Zessly did not affect treatment efficacy, pharmacokinetics and safety. Moreover, this held true in a double switch group originally treated with Remicade.

---

**PMO-49** PATIENT PERCEPTIONS ABOUT CAUSES OF FLARE IN IBD: BASELINE RESULTS FROM THE PREDICCT STUDY

1Spyros Siakavellas*, 1Lauranne Derikx, 1Lisa Der, 1Linda Williams, 1Nikolas Plevris, 1Nathan Constantino-Cooke, 1Kate Covi, 1Gareth-Rhys Jones, 1Charlie Lee, 1PREdiCCt Writing Group. 1The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; 2Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; 3MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

**Introduction** Patient reported outcomes are important end-points in Inflammatory Bowel Disease (IBD) management, but patient perceptions of the causes of disease flare are unknown and thus may reveal novel areas for future study.

---

10.1136/gutjnl-2021-BSG.187

10.1136/gutjnl-2021-BSG.188

10.1136/gutjnl-2021-BSG.186